The user has requested enhancement of the downloaded file. RESULTS: Among the 139 patients who were receiving antiretroviral therapy at the time of survey and who had complete self-reported data, 24 were being treated for their HCV infection, using either pegylated interferon (pegIFN) and ribavirin (RBV) or pegIFN alone.
Impaired anger control as an underappreciated side effect of treatment(s) for chronic HCV infection in HIV-HCV coinfected patients Introduction
With the dramatic improvement in treating many fatal complications of HIV infection, liver disease as a consequence of viral hepatitis C has emerged as a major cause of morbidity and mortality (2, 3) . As an estimated 15-30% of HIV infected patients are also infected with hepatitis C virus (HCV) (4, 5) , HIV-HCV coinfection has become a critical issue because of the interactions between the two viruses (6, 7) which worsen the clinical course of HCV infection (8, 9) . Besides, in patients already being treated with antiretrovirals, HCV infection constitutes an additional burden associated with disabling symptoms, such as fatigue, which impair their quality of life (QOL) (10) . Pegylated interferon alpha (PegIFN) therapy in combination with ribavirin (RBV) is the most efficient treatment for HCV infection (11) .
While anxiety and depression have been extensively described as common side effects of interferon therapy, data on the occurrence and management of other neuropsychiatric disorders such as anger remain scarce (12) (13) (14) (15) . However, anger has been identified as an independent predictor of progression to AIDS (16) and its prevalence in older HIV-infected patients has been reported (17) . In this context, we aimed at investigating the specific impact of treatment for HCV infection on anger expression and control in adult HIV-HCV coinfected patients receiving antiretroviral therapy.
Patients and methods
In 2005, a cross-sectional survey was conducted among 223 coinfected patients being followed-up in two clinical centers located in the south of France (Nice, Marseilles).
Participation in the survey was proposed to all adult HIV-infected patients who were co- Higher scores denote more anger.
Statistical methods
Characteristics of patients being treated for their HCV infection and those who were not were compared using the Wilcoxon rank-sum test (continuous variables) and Fisher's exact test (categorical variables). Correlations between STAXI-2 and QOL dimensions were explored using Pearson's correlation coefficient. Significance level was fixed at α=0.05. Analyses were performed using SAS ® software version 9.1 for Windows (SAS Institute, Cary, NC, USA)
Results
A total of 223 patients agreed to participate in the survey, of whom 152 (68.2%) answered the self-administered questionnaire (respondents). Reasons most frequently given for nonresponse were lack of interest, desire or time. Respondents were not significantly different from non-respondents in terms of age, sex, HIV clinical status (HIV viral load, CDC stage C), and fibrosis stage 1 (results not shown). In order to isolate the specific effect of HCV treatment on patients' irritability and anger, we focused our analysis on patients already being treated for HIV infection at the time of the survey, as they constituted the majority of respondents (n=139, 91.4%). Characteristics of these patients are presented in Table 1 . Most of them were men (64.0%), mean age (standard deviation) was 42.9 (5.4) years and mean time since HCV diagnosis was 10.9 (5.4) years. Seventy-three percent of patients had contracted HCV infection from IV drug abuse. Forty-eight patients were diagnosed with a fibrosis score 1 data on fibrosis stage (biopsy results or FibroTest TM score) were available for half of the patients exceeding F2 (METAVIR) and were therefore treated according to the existing recommendations for HCV treatment. Twenty-four patients were being treated for HCV infection at the time of survey, mainly using a combination therapy of pegIFN and RBV (n=21 patients) and, to a lesser extent, using pegIFN alone (n=3 patients). There was no significant difference between patients being treated for HCV and those who were not with respect to all considered socio-demographic and clinical characteristics, including CES-D global depression score ( 26] (P = 0.02) ( Table 2 ). Anger Control-Out was positively correlated with three domains of QOL (psychological QOL: r = 0.42, P < 0.0001; social relationships QOL: r = 0.26, P = 0.01;
environmental QOL: r = 0.25, P = 0.01).
Discussion
The data presented here suggest that anger control out is associated with pegIFN HCV treatment among patients co-infected with HIV. This result is consistent with literature on anger among HCV mono-infected patients (13, 17, 20) , and provides further information about the association between IFN therapy and neuropsychiatric disorders, as many other studies have focused only on depression. Besides, it underlines the necessity to take into account anger as a characteristic, which can have several implications on the management of HIV and HCV. Indeed, anger has already been shown to be associated with non adherence It is interesting to note that no difference was detected in our study in terms of depression score between those patients being treated and those not being treated for HCV infection. As HIV-infected drug users are more likely to present depressive symptoms (23) , this result could be attributed to the fact that many of the study's patients may already have presented a depressive symptomatology, as more than 70% of them were HIV-infected through IDU.
In addition, our results show that anger control is the main characteristic of anger related to QOL and treatment. Again, this may be due to the high prevalence of patients infected through IDU in the study population. Indeed, a previous study indicated that drug users have a high risk of anger (related) hostility symptoms, are more likely to express anger towards other people or objects in the environment, and have less control over their angry feelings (24) .
Besides, a cross sectional study based on data collected in the pre-HAART era in HIVinfected patients had demonstrated that patients HIV-infected through drug injection report more symptoms and higher overall and physical symptom distress than those belonging to other HIV-transmission categories (25) , which can result in exacerbated angry feelings. In addition, these patients may not be adequately treated for their side effects including anger (26) . However, we pointed out a significant difference concerning angry feelings between HCV treated and not treated patients despite well-balanced proportions of former or active drug users in these two groups, which underlines the determinant impact of HCV treatment on anger.
The failure of the study to find differences on anger dimensions other than control-out between those patients being treated for HCV and those who were not may be due to limited statistical power. Besides, the use of a self-administered questionnaire to address anger issues may be limiting, as it does not take into account perceptions of the patients' environment regarding this problem. Therefore, studies including anger assessment of the patient's environment should be conducted for complementary information. Finally, studies among HCV-infected patients not infected by routes other than drug injection need to be developed in order to disentangle the impact of drug use on anger's dimensions.
Conclusion.
Findings indicate that routine psychosocial assessment of patient's pattern of symptoms should be integrated into HCV and HIV services in order to develop programs to reduce anger expression and to increase anger control ability. Indeed, anger behaviors can potentially be changed using group therapy (27) . Our results need to be taken into account when individualising treatment strategy in co-infected patients in order to minimise possible side effects and optimize patient's clinical outcomes and quality of life. 3 Use of at least one of the following products: cannabis, cocaine, heroin, crack, ecstasy, amphetamins, buprenorphine without medical prescription, LSD or other hallucinogens 
